Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response

Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response

Bibliographic Details
Main Authors:	Sánchez-Rovira, P., Seguí, M. A., Llombart, A., Aranda, E., Antón, A., Sánchez, A., Lomas, M., Jaén, A., Fernández, M., Porras, I., Dalmau, E., Morales, S., de la Haba-Rodríguez, J.
Format:	Online
Language:	English
Published:	Springer Milan 2013
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3776259/

Similar Items

Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial
by: Alba, E, et al.
Published: (2014)

Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis
by: Lin Shui, et al.
Published: (2018-08-01)

Bevacizumab with preoperative chemotherapy versus preoperative chemotherapy alone for colorectal cancer liver metastases: a retrospective cohort study
by: Lu, Zhen-Hai, et al.
Published: (2016)

Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer
by: Geva, Ravit, et al.
Published: (2013)

Prognostic significance of AMPK activation in advanced stage colorectal cancer treated with chemotherapy plus bevacizumab
by: Zulato, E, et al.
Published: (2014)

Prognostic value of a high level of circulating endothelial cells in patients with HER2-recurrent or metastatic breast cancer treated with bevacizumab in combination with paclitaxel and gemcitabine as first-line therapy
by: Manso, L, et al.
Published: (2011)

Chemotherapy plus bevacizumab versus chemotherapy plus cetuximab as first-line treatment for patients with metastatic colorectal cancer: Results of a registry-based cohort analysis
by: Bai, Long, et al.
Published: (2016)

Comparison of bevacizumab plus chemotherapy with chemotherapy alone in advanced non-small-lung cancer patients
by: Tang, Ning, et al.
Published: (2016)

Activity and Safety of Bevacizumab Plus Fotemustine for Recurrent Malignant Gliomas
by: Vaccaro, V., et al.
Published: (2014)

Bevacizumab in the treatment of HER2-negative breast cancer
by: Lorusso, Vito
Published: (2008)

Simulations to Predict Clinical Trial Outcome of Bevacizumab Plus Chemotherapy vs. Chemotherapy Alone in Patients With First‐Line Gastric Cancer and Elevated Plasma VEGF‐A
by: Han, K, et al.
Published: (2016)

Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases
by: De Bruyne, S, et al.
Published: (2012)

Liver resection following FOLFOXIRI plus bevacizumab: a detailed pathological review
by: Walter, H, et al.
Published: (2013)

Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer
by: Miles, D W, et al.
Published: (2013)

A Case of High-Grade Neuroendocrine Carcinoma That Improved with Bevacizumab plus Modified FOLFOX6 as the Fourth-Line Chemotherapy
by: Takeuchi, Satoshi, et al.
Published: (2011)

Effectiveness and Safety of Intensive Triplet Chemotherapy Plus Bevacizumab, FIr-B/FOx, in Young-Elderly Metastatic Colorectal Cancer Patients
by: Bruera, Gemma, et al.
Published: (2013)

Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial
by: Guan, Zhong-Zhen, et al.
Published: (2011)

Biomarkers of reactive resistance and early disease progression during chemotherapy plus bevacizumab treatment for colorectal carcinoma
by: Hayashi, Hidetoshi, et al.
Published: (2014)

Bevacizumab plus chemotherapy in elderly patients with previously untreated metastatic colorectal cancer: single center experience
by: Ocvirk Janja, et al.
Published: (2016-06-01)

Bevacizumab plus chemotherapy in elderly patients with previously untreated metastatic colorectal cancer: single center experience
by: Ocvirk, Janja, et al.
Published: (2016)

Bevacizumab plus chemotherapy as third- or later-line therapy in patients with heavily treated metastatic colorectal cancer
by: Yang, Qiong, et al.
Published: (2015)

Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models
by: Oliva, P, et al.
Published: (2012)

Predictive role of hand–foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer
by: Zielinski, Christoph, et al.
Published: (2016)

Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis
by: Botrel, Tobias Engel Ayer, et al.
Published: (2016)

Neoadjuvant Bevacizumab plus Chemotherapy versus Chemotherapy Alone to Treat Non-Metastatic Breast Cancer: A Meta-Analysis of Randomised Controlled Trials
by: Cao, Li, et al.
Published: (2015)

Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy
by: Fabi, Alessandra, et al.
Published: (2012)

CPT-11/bevacizumab for the treatment of refractory brain metastases in patients with HER2–neu-positive breast cancer
by: Sengupta, S., et al.
Published: (2015)

Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer
by: Miles, D., et al.
Published: (2013)

Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer
by: Della Pepa, Chiara, et al.
Published: (2014)

Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy
by: Munzone, Elisabetta, et al.
Published: (2006)

Neoadjuvant bevacizumab persistently inactivates VEGF at the time of surgery despite preoperative cessation
by: Starlinger, P, et al.
Published: (2012)

Randomized Controlled Trial of Zoledronic Acid plus Chemotherapy versus Chemotherapy Alone as Neoadjuvant Treatment of HER2-Negative Primary Breast Cancer (JONIE Study)
by: Hasegawa, Yoshie, et al.
Published: (2015)

Safety, Effectiveness, and Costs of Bevacizumab-Based Therapy in Southern Spain: A Real World Experience
by: Marín-Pozo, Juan F., et al.
Published: (2016)

Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma
by: Ceresoli, G L, et al.
Published: (2013)

Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab
by: Loupakis, F, et al.
Published: (2013)

Treatment of juxtapapillary hemangioblastoma by intra-arterial (ophthalmic artery) chemotherapy with bevacizumab
by: Jasmine H. Francis, et al.
Published: (2018-09-01)

Efficacy of XELOX plus Bevacizumab in Brain Metastasis from Rectal Cancer
by: Yoshida, Yoichiro, et al.
Published: (2014)

A Case of Biphasic Pulmonary Blastoma Treated with Carboplatin and Paclitaxel plus Bevacizumab
by: Sakata, Shinya, et al.
Published: (2015)

Bevacizumab plus cisplatin and helical tomotherapy in treatment of locally advanced nasopharyngeal carcinoma
by: Li, Jianxiong, et al.
Published: (2015)

Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients
by: Reardon, D A, et al.
Published: (2012)